Inhibition of STAT3 by RNA interference suppresses angiogenesis in colorectal carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Signal transducer and activator of transcription 3 (STAT3) signaling plays a critical role in various cancers, including colorectal carcinoma (CRC).
• STAT3 signaling is implicated in tumor growth, proliferation, and angiogenesis, making it a potential therapeutic target in CRC.

Purpose of the Study:

• To investigate the role of STAT3 signaling in colorectal cancer (CRC) angiogenesis.
• To determine the effect of STAT3 inhibition on CRC cell growth and tumor development in vivo.

Main Methods:

• Constructed HT-29-shSTAT3 cell line using lentivirus-mediated RNAi to inhibit STAT3 expression.
• Assessed cell growth (MTT) and cell cycle (flow cytometry) in vitro.
• Established CRC nude mouse models to monitor tumor growth and microvessel density (MVD) via CD34 staining.
• Quantified mRNA and protein expression of VEGFA, MMP2, and FGF2 using qRT-PCR and Western blot.

Main Results:

• STAT3 knockdown significantly inhibited HT-29 cell growth and increased G0/G1 phase cell proportion.
• In vivo studies showed significantly reduced tumor growth in mice injected with HT-29-shSTAT3 cells.
• Microvessel density (MVD) was significantly lower in the HT-29-shSTAT3 group compared to controls.
• mRNA and protein levels of VEGFA and MMP2 were significantly reduced upon STAT3 knockdown, while FGF2 levels remained unchanged.

Conclusions:

• STAT3 signaling is crucial for colorectal cancer (CRC) cell proliferation and tumor growth.
• Inhibition of STAT3 signaling suppresses angiogenesis in CRC by downregulating VEGFA and MMP2 expression.
• Targeting STAT3 represents a potential therapeutic strategy for inhibiting CRC progression and angiogenesis.